BACKGROUND: An association between fibromyalgia and hepatitis C virus (HCV) has been previously described. However, the relationship between nonalcoholic steatohepatitis (NASH) and fibromyalgia symptoms has not been assessed, though they share several risk factors. AIM: We aimed to assess the factors associated with fibromyalgia symptoms across etiologies of liver disease. METHODS: Patients with cirrhosis due to HCV, NASH, or alcohol were recruited from an outpatient hepatology clinic and administered the Hospital Anxiety and Depression Score, Pittsburgh Sleep Quality Index, and the modified 2010 American College of Rheumatology Diagnostic Criteria for Fibromyalgia. Serum inflammatory markers were measured with standard luminex assays. RESULTS: Of 193 participants, 53 (27 %) met criteria for fibromyalgia. Fibromyalgia symptoms were significantly associated with etiology of liver disease (HCV: 35 %, NASH: 30 %, alcohol-related liver disease: 12 %, p < 0.01). Using logistic regression, mood symptoms (OR 1.14, 95 % CI 1.06, 1.22), sleep disturbance (OR 1.32, 95 % CI 1.16, 1.52), and etiology of liver disease (NASH vs. HCV not different, alcohol vs. HCV OR 0.19, 95 % CI 0.05, 0.63) were associated with fibromyalgia symptoms. If abdominal pain was included in the model, etiology became nonsignificant, indicating that it may be central sensitization due to abdominal pain in patients with chronic liver disease that explains fibromyalgia symptoms rather than the etiology of liver disease or inflammation. CONCLUSIONS: Fibromyalgia symptoms were significantly associated with HCV and NASH cirrhosis and with psychiatric symptoms. Future work should focus on the underlying pathophysiology and management of widespread pain in patients with cirrhosis.
BACKGROUND: An association between fibromyalgia and hepatitis C virus (HCV) has been previously described. However, the relationship between nonalcoholic steatohepatitis (NASH) and fibromyalgia symptoms has not been assessed, though they share several risk factors. AIM: We aimed to assess the factors associated with fibromyalgia symptoms across etiologies of liver disease. METHODS:Patients with cirrhosis due to HCV, NASH, or alcohol were recruited from an outpatient hepatology clinic and administered the Hospital Anxiety and Depression Score, Pittsburgh Sleep Quality Index, and the modified 2010 American College of Rheumatology Diagnostic Criteria for Fibromyalgia. Serum inflammatory markers were measured with standard luminex assays. RESULTS: Of 193 participants, 53 (27 %) met criteria for fibromyalgia. Fibromyalgia symptoms were significantly associated with etiology of liver disease (HCV: 35 %, NASH: 30 %, alcohol-related liver disease: 12 %, p < 0.01). Using logistic regression, mood symptoms (OR 1.14, 95 % CI 1.06, 1.22), sleep disturbance (OR 1.32, 95 % CI 1.16, 1.52), and etiology of liver disease (NASH vs. HCV not different, alcohol vs. HCV OR 0.19, 95 % CI 0.05, 0.63) were associated with fibromyalgia symptoms. If abdominal pain was included in the model, etiology became nonsignificant, indicating that it may be central sensitization due to abdominal pain in patients with chronic liver disease that explains fibromyalgia symptoms rather than the etiology of liver disease or inflammation. CONCLUSIONS:Fibromyalgia symptoms were significantly associated with HCV and NASH cirrhosis and with psychiatric symptoms. Future work should focus on the underlying pathophysiology and management of widespread pain in patients with cirrhosis.
Authors: Charmaine A Stewart; Robert R Auger; Robert Auger; Felicity T B Enders; Donna Felmlee-Devine; Glenn E Smith Journal: J Clin Sleep Med Date: 2014-01-15 Impact factor: 4.062
Authors: Carolina Diaz-Piedra; Andres Catena; Elena Miro; Maria P Martinez; Ana I Sanchez; Gualberto Buela-Casal Journal: Clin J Pain Date: 2014-10 Impact factor: 3.442
Authors: Juan J García; Antonio Cidoncha; María E Bote; María D Hinchado; Eduardo Ortega Journal: Ann Clin Biochem Date: 2013-10-08 Impact factor: 2.057
Authors: Shari S Rogal; Matthew J Chinman; William DeMonte; Sandra Gibson; Stephanie Hoyt-Trapp; Gloria J Klima; Naudia L Jonassaint; Jane M Liebschutz; Kevin L Kraemer; Jessica Merlin Journal: Dig Dis Sci Date: 2022-02-11 Impact factor: 3.487
Authors: Olufunso M Agbalajobi; Theresa Gmelin; Andrew M Moon; Wheytnie Alexandre; Grace Zhang; Walid F Gellad; Naudia Jonassaint; Shari S Rogal Journal: PLoS One Date: 2021-12-17 Impact factor: 3.240